NCT04121286 - A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions

Non-small Cell Lung CancerColorectal CancerPancreatic Ductal CarcinomaEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaBreast CancerOther Solid Tumors

Interventions

DRUG

JAB-3312

JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.

Trial Locations (5)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

Unknown

Peking Union Medical Collage Hospital, Beijing

Peking University Third Hospital, Beijing

Henan Provovential Cancer Hospital, Henan